Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

Recruiting now · Phase 2

Conditions studied: Diffuse Large B Cell Lymphoma (DLBCL)

In brief

This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.

Key facts

Study ID

NCT06647940

Run by

Sun Yat-sen University

People needed

39

Starts

2024-11-01

Expected to finish

2027-03-01

Last updated by the study team

2024-10-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University, — Guangzhou, China, China (enrolling)
• Gansu Cancer Hospital — Lanzhou, Gansu, China (enrolling)
• Dongguan People's Hospital — Dongguan, Guangdong, China (enrolling)
• Fifth Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (enrolling)
• First People's Hospital of Guangzhou — Guangzhou, Guangdong, China (enrolling)
• Guangdong Provincial Hospital of Traditional Chinese Medicine — Guangzhou, Guangdong, China (enrolling)
• Second Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (enrolling)
• First Affiliated Hospital of Shantou University Medical College. — Shantou, Guangdong, China (enrolling)
• Shenzhen People's Hospital — Shenzhen, Guangdong, China (enrolling)
• Zhaoqing First People's Hospital — Zhaoqing, Guangdong, China (enrolling)
• Fifth Affiliated Hospital of Sun Yat-sen University — Zhuhai, Guangdong, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.